Kwality Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 Cr | 67 Cr | 70 Cr | 78 Cr | 92 Cr | 80 Cr | 90 Cr | 84 Cr | 116 Cr | 111 Cr | 111 Cr | 123 Cr |
| Operating expenses (approx.) | 74 Cr | 54 Cr | 54 Cr | 61 Cr | 78 Cr | 63 Cr | 70 Cr | 67 Cr | 90 Cr | 87 Cr | 86 Cr | 94 Cr |
| EBITDA | -5 Cr | 14 Cr | 15 Cr | 17 Cr | 14 Cr | 17 Cr | 20 Cr | 17 Cr | 26 Cr | 24 Cr | 25 Cr | 29 Cr |
| OPM % | -7.3% | 20.4% | 21.9% | 21.4% | 14.7% | 21.7% | 21.8% | 20.7% | 22.4% | 21.7% | 22.8% | 23.6% |
| Other income | 1 Cr | 0.40 Cr | 0.23 Cr | 0.62 Cr | 0.58 Cr | 0.28 Cr | 0.22 Cr | 0.65 Cr | 0.77 Cr | 0.38 Cr | 0.90 Cr | 0.53 Cr |
| Interest | 2 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 2 Cr | 3 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 2 Cr |
| Depreciation | 4 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 4 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr |
| Profit before tax | -10 Cr | 7 Cr | 8 Cr | 10 Cr | 6 Cr | 11 Cr | 13 Cr | 11 Cr | 19 Cr | 17 Cr | 18 Cr | 22 Cr |
| Tax % | 23.5% | 24.9% | 23.9% | 21.3% | 29.2% | 24.9% | 32.6% | 25.2% | 24.1% | 30.0% | 23.5% | 28.4% |
| Net profit | -7 Cr | 5 Cr | 6 Cr | 8 Cr | 4 Cr | 8 Cr | 8 Cr | 9 Cr | 14 Cr | 12 Cr | 14 Cr | 16 Cr |
| EPS (₹) | ₹-7.23 | ₹5.10 | ₹5.99 | ₹7.39 | ₹4.08 | ₹8.04 | ₹8.15 | ₹8.21 | ₹13.95 | ₹11.49 | ₹13.60 | ₹15.42 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 166 Cr | 262 Cr | 456 Cr | 251 Cr | 307 Cr | 370 Cr | Sign in for TTM |
| Operating expenses (approx.) | 151 Cr | 233 Cr | 285 Cr | 207 Cr | 248 Cr | 290 Cr | Sign in for TTM |
| EBITDA | 16 Cr | 29 Cr | 172 Cr | 44 Cr | 59 Cr | 80 Cr | Sign in for TTM |
| OPM % | 9.4% | 11.0% | 37.6% | 17.4% | 19.3% | 21.7% | Sign in for TTM |
| Other income | 0.61 Cr | 2 Cr | 4 Cr | 3 Cr | 2 Cr | 2 Cr | Sign in for TTM |
| Interest | 2 Cr | 3 Cr | 3 Cr | 6 Cr | 10 Cr | 10 Cr | Sign in for TTM |
| Depreciation | 3 Cr | 6 Cr | 11 Cr | 15 Cr | 20 Cr | 18 Cr | Sign in for TTM |
| Profit before tax | 11 Cr | 21 Cr | 162 Cr | 26 Cr | 31 Cr | 54 Cr | Sign in for TTM |
| Tax % | 30.7% | 30.0% | 25.8% | 24.6% | 24.1% | 26.5% | Sign in for TTM |
| Net profit | 8 Cr | 15 Cr | 120 Cr | 19 Cr | 24 Cr | 40 Cr | Sign in for TTM |
| EPS (₹) | ₹7.28 | ₹14.60 | ₹115.64 | ₹18.16 | ₹22.76 | ₹38.36 | Sign in for TTM |
| Dividend payout % | — | — | 0.0% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr |
| Reserves | 27 Cr | 51 Cr | 171 Cr | 189 Cr | 213 Cr | 253 Cr |
| Borrowings | — | — | — | 90 Cr | 98 Cr | 112 Cr |
| Other liabilities | 68 Cr | 105 Cr | 159 Cr | 64 Cr | 74 Cr | 72 Cr |
| Total liabilities | 105 Cr | 166 Cr | 341 Cr | 354 Cr | 394 Cr | 447 Cr |
| Fixed assets (net) | — | — | — | 120 Cr | 139 Cr | 144 Cr |
| CWIP | — | — | — | 14 Cr | 0.0000 Cr | 0.0000 Cr |
| Investments | 5 Cr | 5 Cr | 0.78 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
| Other assets | 75 Cr | 106 Cr | 228 Cr | 218 Cr | 243 Cr | 284 Cr |
| Total assets | 105 Cr | 166 Cr | 341 Cr | 354 Cr | 394 Cr | 447 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 64 Cr | 41 Cr | 43 Cr | 53 Cr |
| Cash from investing | — | — | -63 Cr | -48 Cr | -26 Cr | -29 Cr |
| Cash from financing | — | — | 6 Cr | 0.99 Cr | -17 Cr | -14 Cr |
| Net cash flow | — | — | 7 Cr | -6 Cr | -0.81 Cr | 10 Cr |
| Free cash flow (OCF − Capex) | — | — | 9 Cr | -6 Cr | 13 Cr | 29 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 33.7% | 36.6% | 88.9% | 9.9% | 12.4% | 16.6% |
| ROE % | 20.2% | 24.8% | 66.2% | 9.7% | 10.7% | 15.2% |
| Debtor days | 84 | 50 | 55 | 104 | 136 | 152 |
| Inventory days | 36 | 38 | 97 | 277 | 186 | 184 |
| Days payable | — | — | — | 113 | 105 | 123 |
| Cash conversion cycle | 120 | 88 | 153 | 268 | 217 | 213 |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.45 | 0.44 | 0.43 |
| Current ratio | 1.24 | 1.35 | 1.75 | 1.65 | 1.60 | 1.67 |
| Net debt / EBITDA | -0.09 | -0.20 | -0.08 | 2.00 | 1.62 | 1.25 |
Compare with peers
Loading peers…